Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Denali TherapeuticsDNLI -1.87%33 Quick Ratio is 8.32 as of Jun. 2026, which is 22% below its 10-year median of 10.66. GuruFocus rates DNLI with a GF Score™ of 33/100. The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Denali Therapeutics ranks better than 73.42% on this metric.
Denali Therapeutics (NAS:DNLI) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Denali Therapeutics Quick Ratio Related Terms
Denali Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Denali Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Denali Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Denali Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (DNLI) has a Quick Ratio of 8.32 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Denali Therapeutics and its competitors. This is 22% below median its historical median of 10.66. Over the past decade, Denali Therapeutics' Quick Ratio has ranged from 2.37 to 28.92. According to the industry distribution chart, Denali Therapeutics ranks #375 out of 1411 companies in the Biotechnology industry, placing it in the top 26.6%.
Is Denali Therapeutics' Quick Ratio too high?
Denali Therapeutics' current Quick Ratio of 8.32 is 22% below median its 10-year median of 10.66. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 28.92. The Biotechnology industry median Quick Ratio is 3.58. Denali Therapeutics' value of 8.32 is 132.4% above this industry median. Based on the distribution chart, Denali Therapeutics ranks #375 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Denali Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Denali Therapeutics' Quick Ratio compare to RCUS and ALMS?
According to the Biotechnology industry distribution chart, Denali Therapeutics ranks #375 out of 1411 companies for Quick Ratio. This puts Denali Therapeutics in the upper half of its industry. The industry median Quick Ratio is 3.58. Denali Therapeutics' value of 8.32 is 132.4% above this benchmark. Historically, Denali Therapeutics' own Quick Ratio has ranged from 2.37 to 28.92 over the past decade. While the company's 10-year median is 10.66 vs. the industry median of 3.58, Denali Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.58, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denali Therapeutics's current Quick Ratio of 8.32 is 132.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Denali Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denali Therapeutics's current Quick Ratio is 8.32, which is 22% below median its own 10-year median of 10.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denali Therapeutics stock overvalued right now?
Denali Therapeutics (DNLI) has a current Quick Ratio of 8.32. The current Quick Ratio is 8.32, which is 22% below median its 10-year median of 10.66 and 132.4% above the Biotechnology industry median of 3.58. Denali Therapeutics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Denali Therapeutics (DNLI), the current Quick Ratio is 8.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
33GF Score
Get the complete analysis for DNLI
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DNLI has been successfully added to your 
